Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting

With the gradual improvement of treatment regimens, the survival time of multiple myeloma (MM) patients has been significantly prolonged. Even so, MM is still a nightmare with an inferior prognosis. B-cell maturation antigen (BCMA) is highly expressed on the surface of malignant myeloma cells. For t...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Ruiting, Lu, Wenyi, Zhang, Yi, Cao, Xinping, Jin, Xin, Zhao, Mingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936073/
https://www.ncbi.nlm.nih.gov/pubmed/35320942
http://dx.doi.org/10.3389/fimmu.2022.839097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936073/
https://www.ncbi.nlm.nih.gov/pubmed/35320942
http://dx.doi.org/10.3389/fimmu.2022.839097

Ejemplares similares